Talon Resources Targets Ontario Gold Growth After AIM Move and Eagle Lake Acquisition, CEO Says. Watch here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksABC.L Regulatory News (ABC)

  • There is currently no data for ABC

Director/PDMR Shareholding

29 Mar 2010 15:45

RNS Number : 3606J
ABCAM Plc
29 March 2010
 



For immediate release

29 March 2010

ABCAM PLC

("Abcam" or "the Company")

PDMR Dealings

Cambridge, UK: Abcam plc (AIM: ABC), the rapidly growing bioscience company that markets antibodies via its own online catalogue, has today been notified of the following transactions under the Abcam plc Share Incentive Plan ("the SIP") to the benefit of the PDMRs:

Name

Partnership Shares purchased on 26 March 2010 at 1215 pence per share

Matching Shares

awarded on

26 March 2010 at 1215 pence per share

Subsequent Beneficial Interest in the Company

Subsequent percentage holding of issued share capital

Mark Bushfield

11

11

73

0.0002%

Philippe Cotrel

10

10

343

0.0010%

 

The risk of forfeiture attached to the Matching Shares will normally be removed on the third anniversary of the award subject to continued employment and the retention of the Partnership Shares in connection with which they were awarded. No consideration was paid by the above grantees for the award of the Matching Shares and no consideration is due on their release.

The Company has also been notified that on 29 March 2010, Jane Cooke, a PDMR of the Company, exercised share options over 5654 ordinary shares of 1 pence each in the Company at an exercise price of 280p per share. Following this transaction, Mrs Cooke's total beneficial interest in the Company is 9551 ordinary shares representing approximately 0.03 per cent. of the current issued share capital of the Company. 

For further information please contact:

Abcam

+ 44 (0) 1223 696000

Jonathan Milner, Chief Executive Officer

Jeffrey Iliffe, Chief Financial Officer

Numis Securities

+ 44 (0) 20 7260 1000

Michael Meade / Nick Westlake - Nominated Adviser

James Black - Corporate Broking

Buchanan Communications

+ 44 (0) 20 7466 5000

Mark Court / Stasa Filiplic

 

 

Notes for editors:

About Abcam plc

Abcam is a producer and distributor of research-grade antibodies headquartered in Cambridge, United Kingdom, with subsidiaries in Cambridge, Massachusetts, Tokyo and Hong Kong. Abcam was admitted to AIM in November 2005 and trades under the ticker symbol ABC. The Company produces and distributes its own and third-party produced antibodies and related products to academic and commercial users throughout the world. Product ordering is available through the Company's website www.abcam.com, where customers are also able to access up-to-date and detailed technical product data sheets. All the antibodies are sold under the Abcam brand name. Abcam's mission is to develop the largest catalogue of the best antibodies in the world, with the vision of becoming a global leader in the wider protein detection and regulation markets. Abcam now has a rapidly growing online catalogue and as at 31 December 2009 it contained 57,960 products, most of which are antibodies, from over 250 suppliers. Abcam employs 250 staff in its four operating companies.

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
RDSZKLFLBXFXBBV
Date   Source Headline
2nd Mar 201812:43 pmRNSTotal Voting Rights
19th Feb 20188:44 amRNSBlock listing Interim Review
2nd Feb 20185:57 pmRNSHolding(s) in Company
1st Feb 201812:26 pmRNSTotal Voting Rights
22nd Jan 20187:00 amRNSAbcam Signs Exclusive License Agreement with Roche
18th Jan 201812:02 pmRNSHolding(s) in Company
8th Jan 201812:00 pmRNSAbcam present at J.P. Morgan Healthcare Conference
5th Jan 20187:00 amRNSHalf Year Trading Update
3rd Jan 20189:10 amRNSTotal Voting Rights
12th Dec 201710:37 amRNSDirector/PDMR Shareholding
1st Dec 20173:07 pmRNSTotal Voting Rights
15th Nov 20177:00 amRNSResult of AGM and Directorate Change
14th Nov 20177:00 amRNSAGM Statement
6th Nov 20174:48 pmRNSDirector/PDMR Shareholding
6th Nov 20174:42 pmRNSDirector/PDMR Shareholding
6th Nov 20174:40 pmRNSDirector/PDMR Shareholding
1st Nov 20174:46 pmRNSTotal Voting Rights
30th Oct 20179:55 amRNSDirector/PDMR Shareholding
17th Oct 20173:06 pmRNSHolding(s) in Company
11th Oct 20177:00 amRNSDirectorate Change
3rd Oct 201711:16 amRNSTotal Voting Rights
22nd Sep 20173:32 pmRNSAnnual Financial Report
22nd Sep 20177:00 amRNSDirector/PDMR Shareholding
18th Sep 20174:36 pmRNSDirector/PDMR Shareholding
11th Sep 20177:00 amRNSPreliminary Results
1st Sep 20179:41 amRNSTotal Voting Rights
25th Aug 201711:00 amRNSHolding(s) in Company
17th Aug 201710:00 amRNSHolding(s) in Company
9th Aug 20173:18 pmRNSBlock listing Interim Review
1st Aug 20179:45 amRNSTotal Voting Rights
27th Jul 20177:00 amRNSPre-Close Period Update
3rd Jul 20179:54 amRNSTotal Voting Rights
7th Jun 20174:23 pmRNSDirector/PDMR Shareholding
1st Jun 20172:41 pmRNSTotal Voting Rights
18th May 20173:17 pmRNSApplication for admission to trading
18th May 20177:00 amRNSFinal Performance-Based AxioMx Milestone Payment
3rd May 201711:25 amRNSDirector/PDMR Shareholding
2nd May 201710:27 amRNSTotal Voting Rights
18th Apr 20172:24 pmRNSDirector/PDMR Shareholding
10th Apr 20173:37 pmRNSDirector/PDMR Shareholding
3rd Apr 20171:53 pmRNSTotal Voting Rights
23rd Mar 20177:00 amRNSDirector/PDMR Shareholding
21st Mar 20177:00 amRNSDirector/PDMR Shareholding
6th Mar 20177:00 amRNSInterim Results
1st Mar 20174:05 pmRNSTotal Voting Rights
9th Feb 20178:52 amRNSBlock listing Interim Review
1st Feb 201712:09 pmRNSTotal Voting Rights
10th Jan 20177:00 amRNSHalf Year Trading Update
3rd Jan 20174:34 pmRNSTotal Voting Rights
15th Dec 201611:19 amRNSDirector/PDMR Shareholding

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.